This talk highlights the development of a novel class of skin-applied intracutaneous electrochemical biosensors that facilitate the quantification of relevant metabolomic, electrolytic, hormonal, and neurochemical information in a continuous, real-time fashion.
Dr. Joshua Windmiller is an internationally-recognized expert in wearable electrochemical biosensor technology. His Ph.D. research, funded by a Powell Foundation fellowship, focused on the development of printed biosensors, bioelectronics, and biofuel cells. He has published over 50 manuscripts in peer-reviewed journals and conference proceedings and has eleven US patents issued or pending. Dr. Windmiller, a Gordon Fellow, NIH SHIFT awardee, and two-time NIH Lab-to-Marketplace awardee is the recipient of the Printed Electronics USA 2010 Academic R&D award for his developments in textile-based printed bioelectronics. He completed a postdoctoral fellowship in the Laboratory for NanoBioElectronics at UCSD in 2013, where he was supported by the von Liebig Center for Entrepreneurism and led a commercialization grant sponsored by the DOE. For his successful product development activities leading to the commercialization of novel printed bioelectronic paradigms, he received the Printed Electronics USA 2014 Product Development award. He currently serves as the CTO of Biolinq, a startup that he co-founded devoted to the development of the novel biosensing modalities he has invented for application in the personal wellness and healthcare domains.
Biolinq Incorporated (La Jolla, CA), founded as Electrozyme LLC in 2012, is an early-stage startup devoted to the development of novel electrochemical sensor and biosensor paradigms for applications in diverse verticals including the healthcare, wellness, sports / fitness, military, environmental monitoring, and forensics domains. The Company leverages its core competencies, which includes its extensive expertise computational systems physiology and chemometrics, its ability to synthesize solid-state biosensors containing engineered surfaces exhibiting selectivity towards chemical constituents in various samples, and its ability to scale its bio-/sensor paradigms by leveraging widely-deployed, low-cost manufacturing paradigms. The Company seeks to exploit its core competencies and deep-rooted expertise in the electrochemical quantification of chemical compounds by formulating partnerships with key players in its selected verticals to provide its partners with novel sensing capabilities that are amenable to cost and scaling considerations. An IP-driven company, Biolinq is proactively engaged in various stages of technology development, scientific validation, and system integration and is able to provide its partners with solutions ranging from reference designs to fully-assembled turnkey products.